Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066899 | 0.88 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL28564227 | 0.81 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL4982176 | 0.80 | SLC7A5 (0.41) | SLC7A5DPP4DPP8DPP9 | |
| SCHEMBL4966689 | 0.77 | SLC7A5 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL3396707 | 0.75 | SLC7A5 (0.37) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL28534814 | 0.75 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL15173244 | 0.75 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL10588085 | 0.75 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL15173245 | 0.75 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL28518732 | 0.74 | ANPEP (0.53) | SLC7A5SLC1A3SLC1A2SLC1A1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1018345-B1 | WATER SOLUBLE DRY COMPOSITIONS | OTSUKA PHARMA CO LTD (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080050438-A1 | Dry compositions | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-02-28 | — | — | US | disclosed |
| EP-1254944-B1 | DRY COMPOSITIONS CONTAINING HYDROPHOBIC AMINO ACID | OTSUKA PHARMA CO LTD (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20060057106-A1 | Freeze-dried interferon-y composition for transpulmonary administration and inhalation system therefor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1569681-A1 | FREEZE-DRIED INTERFERON-GAMMAD; COMPOSITION FOR TRANSPULMONARY ADMINISTRATION AND INHALATION SYSTEM THEREFOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-09-07 | — | — | EP | disclosed |
| EP-0869816-B1 | DRY COMPOSITIONS COMPRISING HYDROPHOBIC STABILIZERS | OTSUKA PHARMA CO LTD (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004054605-A1 | FREEZE-DRIED INTERFERON-Ϝ COMPOSITION FOR TRANSPULMONARY ADMINISTRATION AND INHALATION SYSTEM THEREFOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-01 | — | — | WO | disclosed |
| EP-1424066-A1 | Dry compositions comprising hydrophobic stabilisers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20030138402-A1 | Dry compositions | OTSUKA PHARMACEUTICAL CO., LTD. | 2003-07-24 | — | — | US | disclosed |
| US-20030045481-A1 | Dry compositions containing hydrophobic amino acid | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| US-6479048-B2 | FOAM INHIBITOR COMPRISING HYDROPHOBIC AMINO ACID WHICH IS SUITABLE FOR INHIBITING FOAMING INDUCED WHEN DISSOLVING A DRY COMPOSITION CONTAINING SACCHARIDE; PREFERABLY HAS A HYDROPATHY INDEX OF NOT LESS THAN 2. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| EP-1254944-A1 | DRY COMPOSITIONS CONTAINING HYDROPHOBIC AMINO ACID | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6337067-B1 | FOR INHIBITING FOAMING CAUSED WHEN DISSOLVING A CONVENTIONAL DRY COMPOSITION CONTAINING A SACCHARIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-20010049361-A1 | Water-soluble dry compositions | OTSUKA PHARMACEUTICAL CO., LTD. | 2001-12-06 | — | — | US | disclosed |
| EP-1018345-A1 | WATER SOLUBLE DRY COMPOSITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |